Bahn, D
Targeted Cryoablation of the Prostate: 7_Year Outcomes in the Primary Treatment of Prostate Cancer
Urology 2002;60(2A):3-11
Bittner, N
Primary causes of death after permanent prostate brachytherapy
IJROBP 2008;72(2):433-440
Bittner, N
Primary causes of death after permanent prostate brachytherapy
IJROBP 2008;72(2):433-440
Boorjian,S
Mayo Clinic Validation of the D'Amico Risk Group Classification for Predicting Survival…
J. Urology 2008;179():1354-1361
Busch, J
Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a single-centre experience
BJU Int 2012;110(11):E985-90
Critz, F
10 Year disease free survival rates after simultaneous irradiation fro prostate cancer with a focus on calulation and methodology
J. Urology 2004;172():2232-2338
Critz, FA
25-year disease-free survival rate after irradiation for prostate cancer calculated with the prostat specific antigen definition of recurrences used for radical prostatectomy
J Urol 2013;189(3):878-83
Crouzet, S
Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncological outcomes and morbidity in 1002 patients
Eur Urol 2013;epub Apr 30():
Cury, FL
Single-fraction high-dose-rate brachytherapy and hypofractionated exteranl beam radiation therapy in the treatment of intermediate-risk prostate cancer- long term results
IJROBP 2012;82(4):14717-23
Dattoli, M
Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features
Cancer 2007;110(3):551-555
Dattoli, M
Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Irradiation and Brachytherapy
Journal of Oncology 2010;2010():Article ID 471375 6pgs.
Demanes, D J
Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation
Am J. Clinical Oncology 2009;32(4):342-347
Galalae, R
Long-term outcome by risk factors using conformal high dose brachy boost with or without Neoadjuvant androgen suppression for localized prostate cancer
IJROBP 2004;58(4):1048-1055
Galalae, R
Hypofractionated Conformal HDR Brachytherapy in Hormone Naïve Men with Localized Prostate Cancer: Is Escalation to Very High Biologically Equivalent Beneficial in All Progonstic Risk Groups?
Strahlentherapie und Onkologie 2006;181():135-141
Ganzer, R
Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer.
BJU Int 2013;112(3):322-9
Genebes, C
Conventional versus automated implantation of loose seeds in prostate brachytherapy: analysis of dosimetric and clinical results
IJROBP 2013;87(4):651-58
Herbert, C
Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: A population-based cohort study
Radiother Oncol 2012;103(2):228-32
Hinnen, K
Long-Term Biochemical and Survival Outcome of 921 Patients Treated with I125 Permanent Prostate Brachytherapy
IJROBP 2010;76(5):1433-1438
Ho, A
Radiation Dose Predicts for Biochemical Control in Intermediate-risk Prostaste Cancer Patients Treated with Low-dose rate Brachytherapy
IJROBP 2009;75(1):16-22
Ho, A
Radiation Dose Predicts for Biochemical Control in Intermediate-risk Prostaste Cancer Patients Treated with Low-dose rate Brachytherapy
IJROBP 2009;75(1):16-22
Izard, M
Long-term outcome for prostate cancer using pseudo pulse-dosed rate brachytherapy, external beam radiotherapy, and hormones
Brachytherapy 2013;12(6):608-14
Khor, R
Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs. external beam radiation therapy alone for prostate cancer
IJROBP 2013;85(3):1679-85
Khor, R
Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs. external beam radiation therapy alone for prostate cancer
IJROBP 2013;85(3):1679-85
Klein, E
Outcomes For Intermediate Risk Prostate Cancer: Are There Advantage For Sugery, External Beam, or Brachytherapy
Urologic Oncology 2009;27():67-71
Klein, E
Outcomes For Intermediate Risk Prostate Cancer: Are There Advantage For Sugery, External Beam, or Brachytherapy
Urologic Oncology 2009;27():67-71
Klein, E
Outcomes For Intermediate Risk Prostate Cancer: Are There Advantage For Sugery, External Beam, or Brachytherapy
Urologic Oncology 2009;27():67-71
Kotecha, R
Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer
Brachytherapy 2013;12(1):44-49
Kuban, D
Long-Term Multi-Institutional Analysis of Stage T1-T2 Prostate Cancer Treated with Radiotherapy in the PSA Era
IJROBP 2003;57(4):915-928
Kupelian, P
Improved Biochemical Relapse-Free Survival With Increased Radiation Doses in Patients With Locaized Prostate Cancer: The Combined Experience of Nine Institutions in 1994 and 1995
IJROBP 2005;61(2):415-419
Kupelian,P
Radical Prostatectomy, External Beam Radiotherapy <72 Gy, External Beam Radiotherapy ≥72 Gy, Permanent Seed Implantation, or Combined Seeds/External Beam Radiotherapy for Stage T1-T2 Prostate Cancer
IJROBP 2004;58(1):25-33
Kupelian,P
Radical Prostatectomy, External Beam Radiotherapy <72 Gy, External Beam Radiotherapy ≥72 Gy, Permanent Seed Implantation, or Combined Seeds/External Beam Radiotherapy for Stage T1-T2 Prostate Cancer
IJROBP 2004;58(1):25-33
Kupelian,P
Radical Prostatectomy, External Beam Radiotherapy <72 Gy, External Beam Radiotherapy ≥72 Gy, Permanent Seed Implantation, or Combined Seeds/External Beam Radiotherapy for Stage T1-T2 Prostate Cancer
IJROBP 2004;58(1):25-33
Kupelian,P
Radical Prostatectomy, External Beam Radiotherapy <72 Gy, External Beam Radiotherapy ≥72 Gy, Permanent Seed Implantation, or Combined Seeds/External Beam Radiotherapy for Stage T1-T2 Prostate Cancer
IJROBP 2004;58(1):25-33
Lawton, C
Long-term results of an RTOG phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate
IJROBP 2012;82(5):e795-e801
Louis, AS
Oncologic outcomes following radical prostatectomy in the active surveillance era.
Can Urol Assoc J 2013;7(7,8):E475-80
Marina, O
Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients
Brachytherapy 2014;13(1):59-67
Marshall, R
Treatment outcomes and morbidity following definitive brachytherapy with or without external beam radiation for the treatment of localized prostate cancer: 20-year experience at Mount Sinai Medical Center
Urol Oncol 2013;32(1):38e1-7
Martin, A-G
Permanent Prostate Implant Using High Activity Seeds & Inverse Planning With Fast Simulated Annealing Algorithum: A 12-Year Canadian Experience
Int. J. Rad Onc/Bio 2007;67(2):334-341
Menon, M
Biochemical Recurrence Following Robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up
Eur. Urol. 2010;58():838-46
Merrick, G
Prognostic Significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy
J. Urology 2005;66(5):1048-1053
Merrick, G
Androgen deprivation therapy dose not impact cause specific overall survival after permanent prostate brachytherapy
IJROBP 2006;65(3):669-677
Michalski, J
Clinical outcomes of patients treated with 3D conformal radaiation therapy (3D-CRT) for prostate cancer on RTOG 9406.
IJROBP 2012;83(3):e363-70
Morris, WJ
Population-based 10-year oncological outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer
Cancer 2013;119(8):1537-46
Moyad, M
STATINS, ESPECIALLY ATORVASTATIN, MAY FAVORABLY INFLUENCE CLINICAL PRESENTATION AND BIOCHEMICAL PROGRESSION-FREE SURVIVAL AFTER BRACHYTHERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER
Urology 2005;66(6):1150-1154
Mullins, JK
The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary.
J Urol 2012;188(6):2205-10
Munro, NP
Outcomes for Gleason 7, intermediate risk, localized prostate cancer treated with iodine-125 monotherapy over 10 years.
Radiotherapy & Oncology 2010;96(1):34-37
Ohashi, T
Outcomes following iodine-125 prostate brachytherapy with or without neoadjuvant androgen deprivation
Radiother & Oncol 2013;109():241-45
Phan, T
High dose rate brachytherapy as a boost for the treatment of localized prostate cancer
J. Urology 2007;177():123-127
Pollack, A
Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer
J Clin Oncol 2013;31(31):3860-68
Potters, l
12-Year Outcomes Following Permanent Prostate Brachytherapy in Patients With Clinically Localized Prostate Cancer
J. Urology 2005;173():1562-1566
Rossi, C. Jr.
Conformal proton beam radiation therapy for prostate cancer: Concepts and clinical results.
Community Oncology 2007;4():235-240
Sabolch, A
Gleason Pattern 5 is the Greatest Risk Factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation
IJROBP 2011;81(4):e351-60
Sekiguchi, A
125 Iodine monotherapy for Japanese men with low-and intermediate-risk prostate cancer: outcomes after 5-years of follow-up.
J Radiat Res. 2014;55(2):328-33
Sooriakumaran, P
Biochemical Recurrence After Robot-assisted Radical Prostatectomy in a European Single-centre Cohort with a
Minimum Follow-up Time of 5 Years
Eur Urol 2012;62(5):768-74
Spratt, DE
Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer
IJROBP 2013;85(3):686-92
Stone, N.
Local control Following Permanent Prostate Brachytherapy: Effect of High Biologically Effective Dose on Biopsy Results and Oncologic Outcomes
IJROBP 2010;76(2):355-360
Taira, A
Natural History of Clinically Staged Low- and Intermediate Risk Prostate Cancear Treated With Monotherapeutic Permanent Interstitial Brachytherapy
IJROBP 2010;76(2):349-354
Thames, H
Low/ Int Increasing External Inter Beam Dose for T1-T2 High Inter Prostate Cancer: Effect on Risk Groups
Int. J. Rad Onc/Bio 2006;65(4):975-981
Thames, H
Mid/ Increasing External Beam Dose for T1-T2 Prostate Cancer: Effect on Risk Groups
Int. J. Rad Onc/Bio 2006;65(4):975-981
Thames, H
Hi/ Increasing External Beam Dose for T1-T2 Prostate Cancer: Effect on Risk Groups
Int. J. Rad Onc/Bio 2006;65(4):975-981
Thüroff, S
Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years
J Urol 2013;190(2):702-10
Tran, A
Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial Brachytherapy monotherapy
Radiotherapy & Oncol 2013;109(2):235-40
Vassil, AD
Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation, or permanent seed implantation
Urology 2010;76(5):1251-57
Vassil, AD
Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation, or permanent seed implantation
Urology 2010;76(5):1251-57
Vassil, AD
Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation, or permanent seed implantation
Urology 2010;76(5):1251-57
Vora, S
Nine-year outcome and toxicity in patients treated with IMRT for localized prostate cancer
J Urol 2013;In Press(02/06/2013 00:00:00):
Zelefsky, M
Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation
IJROBP 2007;67(2):327-333
Zelefsky, M
Long Term Outcome of High Dose Intensity Modulated Radiation Therapy for Patients With Clinically Localized Prostate Cancer
J. Urology 2006;176():1415-1419
Zumsteg, Z
(Fav. Risk) A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy
Eur Urol 2013;64(6):895-902
Zumsteg, Z
(Unfav. Risk) A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy
Eur Urol 2013;64(6):895-902
Zumsteg, Z
(+ ADT)Short-term androgen-deprivation therapy improves prostate cancer-specific mortality on intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy
IJROBP 2013;85(4):1012-7
Zumsteg, Z
(-ADT)Short-term androgen-deprivation therapy improves prostate cancer-specific mortality on intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy
IJROBP 2013;85(4):1012-7